GenSight Biologics integrates the CAC® Small, CAC® Mid and Small and CAC® All-Tradable Euronext indexes
GenSight Biologics Completes Enrollment of RESCUE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy
GenSight Biologics Reports Interim Financial Results for the First Half of 2017
Publication of the securities note having obtained visa no. 17-297 of the AMF in connection with the capital increase of GenSight Biologics
GenSight Biologics successfully raises €22.5 million from leading investors in the US and Europe
GenSight Biologics launches a capital increase of approximately €20 million
GenSight Biologics reports long-term positive safety and visual acuity results at Week 96 in Phase I/II Study of GS010 for the treatment of LHON
GenSight Biologics to Present Data on GS010 and GS030 at the Annual Meeting of ARVO
GenSight Biologics Appoints Mohamed Genead as Chief Medical Officer
GenSight Biologics Announces the Filing of its 2016 Registration Document
GenSight Biologics to Present GS010 at the 4th Annual Retinal Cell & Gene Therapy Innovation Summit
GenSight Biologics to Present GS010 at the 2017 Annual Meeting of the American Academy of Neurology
GenSight Biologics to Attend Upcoming Investor Conferences
GenSight Biologics to Present Data on GS010 at the 43rd Annual Meeting of NANOS
GenSight Biologics Reports Full Year 2016 Financial Results
GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of LHON
GenSight Biologics receives FDA Orphan Drug Designation for GS030 in Retinitis Pigmentosa
GenSight Biologics reports sustained visual acuity gain at 78 weeks in its Phase I/II Study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON)
GenSight Biologics reports its cash position as of September 30, 2016
GenSight Biologics receives approval to include teenage patients in RESCUE and REVERSE Phase III trials with GS010 in Leber’s Hereditary Optic Neuropathy
The European Medicines Agency (EMA), has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa.
GenSight Biologics confirms the success of its IPO by exercising 88.9% of the over-allotment option.
GenSight Biologics announces the implementation of a liquidity contract with Oddo & Cie
Total size of the offering in the context of the Company’s IPO increased to 5,655,859 new shares, i.e. €45.2 million.
GenSight Biologics announces successful IPO on Euronext Paris : €40 million raised, largest French biotech IPO YTD.
GenSight Biologics launches its Initial Public Offering on the regulated market of Euronext in Paris.
Confirmation of the good safety and tolerability profile of GS010 and improvement of visual acuity in patients with an onset of disease of less than 2 years.
GenSight Biologics announces the registration of its document de base in relation to its planned IPO on Euronext's regulated market in Paris.
GenSight Biologics announced enrollment of the first patient in both RESCUE and REVERSE, two pivotal Phase III trials with lead product candidate GS010.
GenSight Biologics announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) Application for two Phase III clinical trials of GS010.
GenSight Biologics announced that it has completed a Series B preferred stock financing of approximately $36 million.
GenSight Biologics Appoints Thomas Gidoin as Chief Financial Officer & Michael Wyzga to Board of Directors.
GenSight Biologics, Pixium Vision and Fondation Voir et Entendre join forces and benefit from a total €18.5 million funding for SIGHT AGAIN as part of the Investment for the Future.
GenSight Biologics announces the appointment of Jean-Philippe Combal as Chief Operating Officer.
GenSight Biologics announced today the closing of a €32 million Series A financin for Ophthalmic Gene Therapy.